The CD34 þ compartment of grafts for clinical allogeneic hematopoietic cell transplantation (HCT) is very heterogeneous. It contains hematopoietic stem cells and several different progenitor cell populations. This study assesses (1) the content of these populations in clinical grafts from G-CSF-mobilized PBMCs, BM and cord blood, (2) the functional correlation of the graft composition with time to engraftment of neutrophils, platelets and reticulocytes and (3) donor age-related changes. Quantitative flow cytometry showed that the distribution of the progenitor subsets differed significantly between the graft sources and that donor age-related changes occur. In patients after myeloablative allogeneic HCT, accelerated platelet and reticulocyte engraftment correlated with the content of common myeloid and/or megakaryocyte erythroid progenitors in the graft. These findings show that a better understanding of the progenitor compartment in human hematopoietic grafts could lead to improved strategies for the development of cellular therapies, for example in situations where platelet engraftment is delayed.
Introduction
In clinical hematopoietic cell transplantation (HCT), CD34 is used as a surrogate marker to determine the content of hematopoietic stem and progenitor cells in the graft.
Increasing numbers of CD34
þ cells in the graft were significantly associated with accelerated neutrophil and platelet engraftment after HLA-matched related or unrelated myeloablative allogeneic HCT with G-CSF-mobilized PBMCs (G-PBMC). [1] [2] [3] [4] [5] When G-CSF became available clinically as a mobilizing agent, the differences in graft composition between G-PBMC and BM products, as well as the different engraftment kinetics, were clearly documented. 6 Influence of the CD34 þ cell dose on incidence and severity of acute and/or chronic GVHD and decreased relapse rates were discussed. However, the CD34 þ compartment is very heterogeneous. It contains several hematopoietic progenitor subpopulations, such as hematopoietic stem cells (HSCs), common myeloid progenitors (CMPs), granulocyte-macrophage progenitors (GMPs), megakaryocyte erythroid progenitors (MEPs), common lymphoid progenitors (CLPs), T/natural killer (NK) cell progenitors and pro-B cells. [7] [8] [9] [10] [11] [12] [13] [14] These populations have been prospectively isolated in mice and men. 8 The hallmarks of these committed progenitors are a limited life span of several weeks, a loss of self-renewal potential and the in vivo production of a single wave of mature hematopoietic cells of the respective cellular lineage. Functionally, myelo-erythroid progenitors were shown to confer radioprotection, 15 as well as protection against invasive fungal infections, 16 lymphoid progenitors were shown to protect against viral infections post transplant in mice. 17 Furthermore, murine studies of hematopoietic aging showed a shift in the mouse BM progenitor compartment because of an increased percentage of myeloid progenitors in aged mice as compared with young mice. 18, 19 To date, the human progenitor counterparts have not been quantified and functionally correlated with time to engraftment in vivo in patients after allogeneic HCT and donor age-related changes have not been assessed. This study was designed (1) to assess the distribution of the CD34 þ subpopulations in G-PBMC, BM and cord blood (CB) products, (2) to functionally correlate the quantitative content of these CD34 þ subpopulations with time to neutrophil, platelet and reticulocyte engraftment in patients after myeloablative allogeneic HCT and (3) to assess donor age-related changes.
Materials and methods
Hematopoietic stem/progenitor cell products G-PBMC (n ¼ 33), BM (n ¼ 7) and CB (n ¼ 7) products from healthy donors were analyzed by fluorescenceactivated cell sorting (FACS) after written informed consent at the University Hospital Basel from October 2007 to August 2009. Only CB donations too small for CB banking (with a total nucleated cell count of o100 Â 10 7 ) were used for the study after informed consent from the mother. The local ethics committee approved the study. Mobilization of G-PBMC was performed by application of G-CSF for five consecutive days at a dose of 10 mg per kg body weight per day.
Patient selection
A total of 26 patients undergoing myeloablative allogeneic HCT at the University Hospital Basel both with G-PBMC (n ¼ 23) or BM (n ¼ 3) and with available FACS analysis of the graft product were included. Patients were transplanted from HLA-identical siblings (n ¼ 18) or matched unrelated donors (n ¼ 8) for a variety of diseases (Table 1) . No growth factors were applied post transplant. Additional 10 G-PBMC and 4 BM products were analyzed, but patients were excluded from the engraftment analysis because they received either a non-myeloablative conditioning regimen (eight G-PBMC, 1 BM), were HLA mismatched (two G-PBMC) or the products were harvested for other transplantation centers (three BM). The CB products were not used for transplantation.
Flow cytometry evaluation of graft composition CD34 þ cells were enumerated using a single platform bead method according to the guidelines of the international society for hematotherapy and graft engineering. 20 The analysis of the CD34 þ progenitor subpopulations was performed on lineage (Lin)-negative CD34 þ cells. Linpositive cells were excluded by scatter profile and staining with CD3, CD56 and CD19 except for the analysis of Pro-B cells. Within the Lin À CD34 þ fraction the following populations were assessed: CD38 À HSCs,
þ T/NK cell progenitors. 12 The following reagents were used from BD Biosciences (Altschwil, Switzerland) unless otherwise indicated: TruCount reagents for CD34 þ enumeration using CD45 (2D1) FITC, CD34 (8G12) PE and 7-AAD; CD123 (7G3) and CD10 (MEM-78, Invitrogen, Basel, Switzerland) in FITC, CD45RA (HI100) and CD7 (M-T701) in PE, CD38 (HIT2), CD3 (SK7), CD19 (SJ25C1) and CD56 (HCD56, BioLegend, Luzern, Switzerland) in PerCP-Cy5.5, CD34 (8G12) in APC. Lymphocyte populations were analyzed by staining for T cells (CD3 /kg (n ¼ 7). For MEP content, two different cut-off points were investigated because of the overall very low MEP content in G-PBMC grafts: first at the median MEP content (0.009 Â 10 6 /kg), and second at the fourth quartile of MEP content (0.050 Â 10 6 /kg). Definitions of engraftment Time to engraftment was measured in days. Complete blood counts were performed daily, reticulocytes were measured three times per week using the ADVIA120 system (Siemens, Zu¨rich, Switzerland). All patients have engrafted, none of them died before engraftment. Neutrophil engraftment was defined as the first of three consecutive days with an ANC 40.5 Â 10 9 /L (ANC500), platelet engraftment as the first of three consecutive days with platelets 420 Â 10 9 /L (Plt20) in the absence of platelet transfusions, and reticulocyte engraftment as the first of three measurements with reticulocytes 420 Â 10 9 /L (Reti20) in patients with no or minor ABO blood group barrier. An internationally established value for the reticulocyte engraftment after allogeneic HCT does not exist. On the basis of our own experience and by analogy to patients with severe aplastic anemia we retained the value of 420 Â 10 9 /L. 21 
Statistical analysis
The Mann-Whitney test was used for comparison of progenitor content in the different graft sources. For analysis of correlations between progenitor subsets and influence of donor age on graft composition, the Spearman's rank test was used. For correlation of progenitor content with time to engraftment, a univariate Cox regression model was used. Cumulative incidences of engraftment were compared by log-rank statistics (SPSS Software version 16.0).
Results

Distribution and quantification of the CD34
þ subpopulations in G-PBMC, BM and CB products The relative distribution of the CD34 þ subpopulations in % was determined in G-PBMC, BM and CB products. Figures 1a-c . In G-PBMC, the content of CMP was highest, whereas HSC, GMP, Pro-B and T/NK-P content was lowest, when compared with BM or CB. The highest proportion of HSC and GMP was found in CB. As expected, BM contained the greatest number of Pro-B cells and CB the highest of CD7 þ T/NK progenitors. MEP and CLP contents were not significantly different ( Table 2 , Figures 1d and e). As described by others, we found that all subsets of lymphoid progenitors are only present at a very low frequency in G-PBMC products. 22 The distribution of the mature lymphocytes was also coherent with other reports. 23 Correlations between the different CD34 þ subpopulations In G-PBMC products (n ¼ 33), a significant correlation was found between the content (per kg body weight of the recipient) of HSC and CMP (P ¼ 0.014, R 2 ¼ 0.422), HSC and GMP (P ¼ 0.007, R 2 ¼ 0.462), CMP and GMP (P ¼ 0.044, R 2 ¼ 0.353), CMP and MEP (P ¼ 0.004, R 2 ¼ 0.49) and GMP and MEP (P ¼ 0.04, R 2 ¼ 0.359). In BM products (n ¼ 7), a significant correlation was found between the content of HSC and CMP (P ¼ 0.014, R 2 ¼ 0.857). All other analyzed progenitor subsets did not correlate with each other. Next, we analyzed the correlations between the different CD34 þ subpopulations in the subgroup of 23 patients that were available for the engraftment analysis. In these 23 patients transplanted with G-PBMC products we found a correlation between HSC and GMP (P ¼ 0.011, R 2 ¼ 0.520) and between CMP and MEP (P ¼ 0.012, R 2 ¼ 0.515). In these donor-patient pairs, the correlation between HSC and CMP (P ¼ 0.087, R 2 ¼ 0.365), CMP and GMP (P ¼ 0.206, R 2 ¼ 0.274) and GMP and MEP (P ¼ 0.057, R 2 ¼ 0.402) was not significant (Figure 2 ). Only three patients with BM products were available for engraftment analysis, correlations could not be analyzed for this limited number of patients. 
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Correlation of CD34
þ subpopulations with time to engraftment in patients after myeloablative allogeneic HCT The functional correlation between hematopoietic stem/ progenitor content per kg recipient body weight (Table 2) and time to neutrophil, platelet or reticulocyte engraftment was analyzed in patients with G-PBMC grafts (Figures 3  and 4) . For neutrophil engraftment, none of the progenitor populations had a significant impact on time to ANC500 (data not shown). However, for platelet and reticulocyte engraftment, a correlation with the content of total CD34 þ cells/kg was revealed. The correlation for Plt20 was attributed to the content of CMP and MEP/kg (Figure 3 ), for Reti20 engraftment to the content of CMP/kg ( Figure 4 ). All other CD34 þ subpopulations did not correlate significantly with neutrophil, platelet or reticulocyte engraftment (data not shown). With a median follow up of 515 days (range 187-916), no graft loss has occurred so far.
Donor age-related changes in graft composition
To assess whether the effect of CMP and MEP on time to engraftment in our patient cohort was because of a donor age-dependent change in graft composition, the influence of þ T cells contained in the graft with increasing donor age (P ¼ 0.029, R 2 ¼ À0.381) confirmed findings previously reported. 23 In the seven BM donors, we found no significant correlation between progenitor content and increasing donor age. However, the donor age in BM donors ranged from 15 to 39 years (median 34) as compared to a range of 19 to 70 years (median 43) in the 33 G-PBMC donors. In the 23 donorpatient pairs that were included for the engraftment analysis, we found a negative correlation between donor age and total CD34 þ count (P ¼ 0.042, R 2 ¼ À0.427), as well as CMP (P ¼ 0.045, R 2 ¼ À0.422) and MEP (P ¼ 0.029, R 2 ¼ À0.455). No significant influence of donor age on the HSC, GMP, CLP, Pro-B or T/NK-P compartment was observed ( Figure 5 and data not shown). Furthermore, donor age did not have an influence on time to engraftment of neutrophils (as previously described 24 in unrelated donor transplants), platelets or reticulocytes (data not shown) in this limited cohort of donor-patient pairs.
Discussion
In this study we show that clinical G-PBMC, BM and CB grafts used in allogeneic HCT show a distinct distribution pattern of well-defined hematopoietic stem/progenitor cell populations within the Lin À
CD34
þ compartment. This illustrates that the hematopoietic stem/progenitor composition is more complex than just total CD34 þ counts used in clinical routine. The analyzed subsets all represent different stages of maturation and lineage commitment as previously described by others. 11 Therefore, it is likely that kinetics and quality of engraftment not only depend on the graft source and total CD34 þ count as demonstrated earlier 6 but also on the quantitative differences of hematopoietic stem/ progenitor cell populations contained in the grafts.
In this present study, however, only fresh CB units that were too small for CB banking were analyzed. These products were not used for transplantation and no engraftment analysis could be performed. Cryopreservation, freezing and thawing of CB units in routine clinical CB transplantation might affect the selective distribution and survival of any of the CD34 þ progenitor populations. These questions were not assessed in the present study and should be addressed in the future.
In patients receiving allogeneic HCT from G-PBMC products, we found a correlation between the content of total CD34 þ cells, CMP and MEP and time to platelet or reticulocyte engraftment. These results indicate that engraftment kinetics can partially be attributed to the quantity of distinct CD34 þ hematopoietic progenitor subpopulations. A possible explanation for the missing correlation with neutrophil engraftment in our study could be the very high number of myeloid progenitors contained in the grafts and the limited number of donor--patient pairs. Even in very large registry studies, differences in time to neutrophil engraftment with 'low' vs 'high' doses of CD34 þ cells can be very small, whereas time to platelet engraftment shows greater differences. 2 Some investigators did not detect a correlation at all. 4 Furthermore, the cutoffs for defining 'low' and 'high' CD34 þ cell doses and the optimal dose range is still a matter of debate. 1 In our cohort, we could clearly detect a correlation between total CD34
þ , CMP and MEP and time to platelet engraftment.
Donor age-related changes in graft composition and effect on time to engraftment were analyzed in our cohort as murine studies have demonstrated a shift toward myeloid progenitors in the BM of aged mice as compared with young mice. The age range of our seven BM donors was limited from 15 to 39 years (median 34) and might not be representative because BM samples from very young, as well as from donors over 39 years of age, were not available for analysis. Therefore, a donor age-dependent effect on the progenitor compartment might be missed in this small cohort of BM donors. However, in G-PBMC products, increasing donor age was associated with a decrease in transplanted CMP and MEP. Therefore, the effect of CMP and MEP on time to engraftment in this cohort cannot be explained by donor age-related changes in G-CSF-mobilized peripheral blood hematopoietic cell products.
CMP and MEP have a limited life span and are not capable of self renewal. In murine studies of MHCmismatched allogeneic HCT it was shown that in vivo CMP produce a single wave of mature myelo-erythroid cells, that this reconstitution is faster than the reconstitution from HSC, that they do not persist long term and that their progeny is functional in vivo as demonstrated by radioprotection and protection against fungal infections. 15, 16 In our present study, we document a functional correlation for the human counterparts of these progenitors by correlating the progenitor contents in clinical graft products with time to engraftment. A potential future clinical application of these findings could be the add-back of purified CMP and MEP from G-PBMC to accelerate the engraftment of patients undergoing CB transplantation where prolonged transfusion-dependent thrombocytopenia is still a major problem. It has been demonstrated recently that CD34-selected G-PBMC from third party donors Medicine at the University Hospital Basel. Financial support for CA was provided by Krebsliga beider Basel.
